All In Biotech

Drug Trial Radar · NCT07552077

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Aug 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Palvella Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas

Conditions

  • Angiokeratomas

Interventions

  • PTX-022Drug

    topical administration of PTX-022

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: 3 months
  2. Overall Angiokeratoma Investigator Global Assessment (AK-IGA)Time frame: 3 months
  3. Overall Patient Global Impression of Change (PGI-C)Time frame: 3 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Unified Health

    Sherman Oaks, California · Not yet recruiting

  • Cleaver Medical Group

    Dawsonville, Georgia · Recruiting

  • Vividia Dermatology

    Las Vegas, Nevada · Not yet recruiting

  • Epiphany Dermatology

    Southlake, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.